Browsing by Author "Jovanovic, Maja Perunicic (57210906777)"
Now showing 1 - 10 of 10
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes(2015) ;Jovanovic, Maja Perunicic (57210906777) ;Mihaljevic, Biljana (6701325767) ;Jakovic, Ljubomir (21742748500) ;Martinovic, Vesna Cemerikic (21743118200) ;Fekete, Marija Dencic (36652618600) ;Andjelic, Bosko (6507067141) ;Antic, Darko (23979576100) ;Bogdanovic, Andrija (6603686934) ;Boricic, Novica (56515320500) ;Terzic, Tatjana (55916182400) ;Jelicic, Jelena (56180044800)Milenkovic, Sanja (57220419015)Purpose: Despite major advances in the treatment of diffuse large B cell lymphoma (DLBCL), approximately one third of the patients progress or die, suggesting the existence of additional oncogenic events. The purpose of this study was to evaluate the prognostic value of the "Hans classifier", and BCL2 and MYC protein expression and gene alterations in DLBCL patients treated with CHOP or R-CHOP chemotherapy over a 5-year period. Furthermore, we tried to correlate these parameters with the International Prognostic Index (IPI). Methods: The immunohistochemical (IHC) expression of CD10, BCL6, MUM1 and BCL2 on paraffin-embedded formalin-fixed tumor samples from 103 centroblastic DLBCLs was analyzed. IHC expression of MYC and fluorescence in situ hybridization (FISH) for MYC and BCL2 gene alterations was performed on 67 samples using the tissue microarray (TMA) method. Results: The Hans algorithm was not predictive of survival in both therapy groups. No significant difference in BCL2 and MYC alterations or MYC protein expression in relation to complete response (CR), event-free survival (EFS) and overall survival (OS) was observed in our study. High IPI correlated significantly with poor outcome and it was identified as independent prognostic factor for OS and EFS (both p=0.000). The 5-year OS was 61% in the R-CHOP compared to 38% in the CHOP group (p=0.007). Rituximab significantly improved the OS in the BCL2 positive (60 vs 29%, p=0.008), and the BCL6 negative (73 vs 25%, p=0.001) cases. Conclusion: IPI is an independent prognosticator for DLBCL patients and the addition of rituximab significantly improved survival. Furthermore, patients with BCL2+ and BCL6- DLBCL benefited from R-CHOP. - Some of the metrics are blocked by yourconsent settings
Publication BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes(2015) ;Jovanovic, Maja Perunicic (57210906777) ;Mihaljevic, Biljana (6701325767) ;Jakovic, Ljubomir (21742748500) ;Martinovic, Vesna Cemerikic (21743118200) ;Fekete, Marija Dencic (36652618600) ;Andjelic, Bosko (6507067141) ;Antic, Darko (23979576100) ;Bogdanovic, Andrija (6603686934) ;Boricic, Novica (56515320500) ;Terzic, Tatjana (55916182400) ;Jelicic, Jelena (56180044800)Milenkovic, Sanja (57220419015)Purpose: Despite major advances in the treatment of diffuse large B cell lymphoma (DLBCL), approximately one third of the patients progress or die, suggesting the existence of additional oncogenic events. The purpose of this study was to evaluate the prognostic value of the "Hans classifier", and BCL2 and MYC protein expression and gene alterations in DLBCL patients treated with CHOP or R-CHOP chemotherapy over a 5-year period. Furthermore, we tried to correlate these parameters with the International Prognostic Index (IPI). Methods: The immunohistochemical (IHC) expression of CD10, BCL6, MUM1 and BCL2 on paraffin-embedded formalin-fixed tumor samples from 103 centroblastic DLBCLs was analyzed. IHC expression of MYC and fluorescence in situ hybridization (FISH) for MYC and BCL2 gene alterations was performed on 67 samples using the tissue microarray (TMA) method. Results: The Hans algorithm was not predictive of survival in both therapy groups. No significant difference in BCL2 and MYC alterations or MYC protein expression in relation to complete response (CR), event-free survival (EFS) and overall survival (OS) was observed in our study. High IPI correlated significantly with poor outcome and it was identified as independent prognostic factor for OS and EFS (both p=0.000). The 5-year OS was 61% in the R-CHOP compared to 38% in the CHOP group (p=0.007). Rituximab significantly improved the OS in the BCL2 positive (60 vs 29%, p=0.008), and the BCL6 negative (73 vs 25%, p=0.001) cases. Conclusion: IPI is an independent prognosticator for DLBCL patients and the addition of rituximab significantly improved survival. Furthermore, patients with BCL2+ and BCL6- DLBCL benefited from R-CHOP. - Some of the metrics are blocked by yourconsent settings
Publication FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma(2016) ;Mihaljevic, Biljana (6701325767) ;Jelicic, Jelena (56180044800) ;Andjelic, Bosko (6507067141) ;Antic, Darko (23979576100) ;Markovic, Olivera (57205699382) ;Petkovic, Ivan (36629090100) ;Jovanovic, Maja Perunicic (57210906777) ;Trajkovic, Goran (9739203200) ;Bila, Jelena (57208312102) ;Djurasinovic, Vladislava (35172762900) ;Sretenovic, Aleksandra (24170024700) ;Vukovic, Vojin (56180315400) ;Smiljanic, Mihailo (45661914300)Balint, Milena Todorovic (57140127400)The Follicular Lymphoma International Prognostic Index (FLIPI) is widely used in the identification of risk groups among follicular lymphoma (FL) patients. The aim of the present study was to evaluate the prognostic value of FLIPI combined with the Charlson comorbidity index (CCI) and histological grade of lymphoma. 224 newly diagnosed FL patients (median age 56 years) treated with immunochemotherapy were retrospectively analysed. Low FLIPI had 21.0 % of patients, intermediate 28.1 % and high 46.9 %. 50.9 % of patients had no comorbidities. Only 7.1 % of patients had a high CCI score (≥2), while 25.9 % of patients were histological grade 3. Parameters that influenced overall survival were evaluated using Cox regression analysis, in which CCI, FLIPI and histological grade (p < 0.05) retained prognostic significance. By combining these parameters, we have developed the FCG score, which incorporates FLIPI, CCI, and histological grade. This score defines three risk categories (low: 41.5 %; intermediate: 37.5 %; high: 13.4 %), associated with significantly different survival (p < 0.0001); this consequently improves discriminative power by 9.1 % compared to FLIPI. FCG score represents a possible new prognostic index, highlighting the role of the patient’s clinical state and the histological characteristics of disease, as indicated by comorbidity index and histological grade of lymphoma. © 2016, The Japanese Society of Hematology. - Some of the metrics are blocked by yourconsent settings
Publication Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: A single center study(2012) ;Todorovic, Milena (23010544100) ;Radisavljevic, Ziv (16158297200) ;Balint, Bela (7005347355) ;Andjelic, Bosko (6507067141) ;Todorovic, Vera (7006326762) ;Jovanovic, Maja Perunicic (57210906777)Mihaljevic, Biljana (6701325767)Angiogenesis in solid tumors is important for tumor growth, invasion, and metastasis. However, angiogenesis plays also an important role in hematological malignancies. We have analyzed the expression of vascular endothelial growth factor (VEGF) in the leukemic blast cells and microvessel density (MVD) in the bone marrow biopsy samples of the patients with acute lymphoblastic leukemia (ALL). Bone marrow MVD of the patients with ALL was significantly higher compared with normal controls and complete remission (P<0.001), but slightly lower than in patients with relapsed ALL (P>0.05). The bone marrow blast VEGF expression was significantly higher in newly diagnosed ALL patients, with predominant strong VEGF expression as compared with complete remission patients (who had negative or weak VEGF expression) (P<0.05), whereas initial values were slightly lower than in relapsed patients. There was a strong positive correlation between VEGF expression and MVD at presentation of ALL. Stronger expression of VEGF on blast cells indicates shorter overall survival in ALL. Furthermore, initial values of MVD had positive correlation with overall survival and leukemia-free survival (P=0.024 and P=0.017, respectively). Our data suggest that increased angiogenesis (confirmed by immunohistochemical expression of VEGF in leukemic blasts), and MVD may play an important role in the pathophysiology of ALL with prognostic implications. Thus, targeting VEGF pathway may bring the new approach for ALL treatment-using antiangiogenic drugs and tyrosine kinase inhibitors in combination with standard chemotherapy regimens. Copyright © 2012 by Lippincott Williams & Wilkins. - Some of the metrics are blocked by yourconsent settings
Publication Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: A single center study(2012) ;Todorovic, Milena (23010544100) ;Radisavljevic, Ziv (16158297200) ;Balint, Bela (7005347355) ;Andjelic, Bosko (6507067141) ;Todorovic, Vera (7006326762) ;Jovanovic, Maja Perunicic (57210906777)Mihaljevic, Biljana (6701325767)Angiogenesis in solid tumors is important for tumor growth, invasion, and metastasis. However, angiogenesis plays also an important role in hematological malignancies. We have analyzed the expression of vascular endothelial growth factor (VEGF) in the leukemic blast cells and microvessel density (MVD) in the bone marrow biopsy samples of the patients with acute lymphoblastic leukemia (ALL). Bone marrow MVD of the patients with ALL was significantly higher compared with normal controls and complete remission (P<0.001), but slightly lower than in patients with relapsed ALL (P>0.05). The bone marrow blast VEGF expression was significantly higher in newly diagnosed ALL patients, with predominant strong VEGF expression as compared with complete remission patients (who had negative or weak VEGF expression) (P<0.05), whereas initial values were slightly lower than in relapsed patients. There was a strong positive correlation between VEGF expression and MVD at presentation of ALL. Stronger expression of VEGF on blast cells indicates shorter overall survival in ALL. Furthermore, initial values of MVD had positive correlation with overall survival and leukemia-free survival (P=0.024 and P=0.017, respectively). Our data suggest that increased angiogenesis (confirmed by immunohistochemical expression of VEGF in leukemic blasts), and MVD may play an important role in the pathophysiology of ALL with prognostic implications. Thus, targeting VEGF pathway may bring the new approach for ALL treatment-using antiangiogenic drugs and tyrosine kinase inhibitors in combination with standard chemotherapy regimens. Copyright © 2012 by Lippincott Williams & Wilkins. - Some of the metrics are blocked by yourconsent settings
Publication The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma(2012) ;Andjelic, Bosko (6507067141) ;Mihaljevic, Biljana (6701325767) ;Todorovic, Milena (23010544100) ;Bila, Jelena (57208312102) ;Jakovic, Ljubomir (21742748500)Jovanovic, Maja Perunicic (57210906777)The clinical course of patients with follicular lymphoma is variable from a slowly progressive disease to a progressive disease with a survival time of approximately 1 year. Many prognostic models have been suggested to identify high-risk patients. Recent gene profiling analysis showed that the clinical behavior of follicular lymphoma is determined by the properties of the nonmalignant tumor microenvironment. We investigated the role of lymphoma-associated macrophages (LAMs) in tumor tissue in patients with newly diagnosed follicular lymphoma. The LAM was determined immunohistochemically in lymph node tissue sections by anti-CD68 PG-M1 and analyzed through high-power field (HPF) magnification intrafollicularly (IF) and extrafollicularly. In our study, the patients who had an IF LAM count equal to or more than 10/HPF had significantly shorter overall survival (P=0.018) and 3 years of progression-free survival (P=0.034) compared with patients with <10 LAM/HPF. Multivariate analysis indicated that IF LAM/HPF ≥10 and Eastern Cooperative Oncology Group performance status >1 are independent prognostic factors for a poor outcome. © 2011 by Lippincott Williams & Wilkins. - Some of the metrics are blocked by yourconsent settings
Publication The number of lymphoma-associated macrophages in tumor tissue is an independent prognostic factor in patients with follicular lymphoma(2012) ;Andjelic, Bosko (6507067141) ;Mihaljevic, Biljana (6701325767) ;Todorovic, Milena (23010544100) ;Bila, Jelena (57208312102) ;Jakovic, Ljubomir (21742748500)Jovanovic, Maja Perunicic (57210906777)The clinical course of patients with follicular lymphoma is variable from a slowly progressive disease to a progressive disease with a survival time of approximately 1 year. Many prognostic models have been suggested to identify high-risk patients. Recent gene profiling analysis showed that the clinical behavior of follicular lymphoma is determined by the properties of the nonmalignant tumor microenvironment. We investigated the role of lymphoma-associated macrophages (LAMs) in tumor tissue in patients with newly diagnosed follicular lymphoma. The LAM was determined immunohistochemically in lymph node tissue sections by anti-CD68 PG-M1 and analyzed through high-power field (HPF) magnification intrafollicularly (IF) and extrafollicularly. In our study, the patients who had an IF LAM count equal to or more than 10/HPF had significantly shorter overall survival (P=0.018) and 3 years of progression-free survival (P=0.034) compared with patients with <10 LAM/HPF. Multivariate analysis indicated that IF LAM/HPF ≥10 and Eastern Cooperative Oncology Group performance status >1 are independent prognostic factors for a poor outcome. © 2011 by Lippincott Williams & Wilkins. - Some of the metrics are blocked by yourconsent settings
Publication The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas(2016) ;Jelicic, Jelena (56180044800) ;Balint, Milena Todorovic (57140127400) ;Jovanovic, Maja Perunicic (57210906777) ;Boricic, Novica (56515320500) ;Micev, Marjan (7003864533) ;Stojsic, Jelena (23006624300) ;Antic, Darko (23979576100) ;Andjelic, Bosko (6507067141) ;Bila, Jelena (57208312102) ;Balint, Bela (7005347355) ;Pavlovic, Sonja (7006514877)Mihaljevic, Biljana (6701325767)Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC >2.6 in DLBCL and ALC/AMC ≥ 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p < 0.05). In DLBCL, MVD > 42 blood vessels/0.36 mm2 correlated with primary resistant disease (p < 0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p < 0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51–7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08–1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17–23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06–14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s). © 2016, Arányi Lajos Foundation. - Some of the metrics are blocked by yourconsent settings
Publication The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas(2016) ;Jelicic, Jelena (56180044800) ;Balint, Milena Todorovic (57140127400) ;Jovanovic, Maja Perunicic (57210906777) ;Boricic, Novica (56515320500) ;Micev, Marjan (7003864533) ;Stojsic, Jelena (23006624300) ;Antic, Darko (23979576100) ;Andjelic, Bosko (6507067141) ;Bila, Jelena (57208312102) ;Balint, Bela (7005347355) ;Pavlovic, Sonja (7006514877)Mihaljevic, Biljana (6701325767)Prognostic significance of immune microenvironment has been emphasized using the most advanced analysis, with consecutive attempts to reveal prognostic impact of this findings. The aim of this study was to compare and define prognostic significance of clinical parameters, microvessel density (MVD) in tumour tissue and expression of CD44s as adhesive molecule on tumour cells in diffuse large B cell lymphoma-DLBCL, primary central nervous system DLBCL-CNS DLBCL and follicular lymphoma-FL. A total of 202 histopathological samples (115 DLBCL/65 FL/22 CNS DLBCL) were evaluated. Overall response (complete/partial remission) was achieved in 81.3 % DLBCL patients, 81.8 % primary CNS DLBCL and 92.3 % FL. Absolute lymphocyte count-ALC/Absolute monocyte count-AMC >2.6 in DLBCL and ALC/AMC ≥ 4.7 in FL were associated with better event-free survival (EFS) and overall survival (OS) (p < 0.05). In DLBCL, MVD > 42 blood vessels/0.36 mm2 correlated with primary resistant disease (p < 0.0001), poorer EFS and OS (p = 0.014). High CD44s expression in FL correlated with inferior EFS and OS (p < 0.01). In DLBCL, multivariate Cox regression analysis showed that ALC/AMC was independent parameter that affected OS (HR 3.27, 95 % CI 1.51–7.09, p = 0.003) along with the NCCN-IPI (HR 1.39, 95 % CI 1.08–1.79, p = 0.01). Furthermore, in FL, ALC/AMC mostly influenced OS (HR 5.21, 95 % CI 1.17–23.21, p = 0.03), followed with the FLIPI (HR 3.98, 95 % CI 1.06–14.95, p = 0.041). In DLBCL and FL, ALC/AMC is simple and robust tool that is, with current prognostic scores, able to define long-term survival and identify patients with inferior outcome. The introduction of immunochemotherapy might altered the prognostic significance of microenvionmental biomarkers (MVD and CD44s). © 2016, Arányi Lajos Foundation. - Some of the metrics are blocked by yourconsent settings
Publication The WHO diagnostic criteria for polycythemia vera—role of red cell mass versus hemoglobin/hematocrit level and morphology(2018) ;Jakovic, Ljubomir (21742748500) ;Gotic, Mirjana (7004685432) ;Gisslinger, Heinz (7005768562) ;Soldatovic, Ivan (35389846900) ;Sefer, Dijana (6603146747) ;Tirnanic, Mila (57201800783) ;Lekovic, Danijela (36659562000) ;Jovanovic, Maja Perunicic (57210906777) ;Schalling, Martin (58441401300) ;Gisslinger, Bettina (6507974358) ;Beham-Schmid, Christine (6701322682) ;Simonitsch-Klupp, Ingrid (6506605920)Thiele, Jürgen (7202528008)Regarding diagnosis of polycythemia vera (PV), discussion persists about hemoglobin (Hb) and/or hematocrit (Hct) threshold values as surrogate markers for red cell mass (RCM) and the diagnostic impact of bone marrow (BM) morphology. We performed a retrospective study on 290 patients with PV (151 males, 139 females; median age 65 years) presenting with characteristic BM features (initial biopsies, centralized evaluation) and endogenous erythroid colony (EEC) formations. This cohort included (1) a group of 229 patients when following the 2008 versus 256 patients diagnosed according to the 2016 World Health Organization (WHO) guidelines, all presented with increased RCM; (2) masked PV patients with low Hb (n = 143)/Hct (n = 45) recruited from the 2008 WHO cohort; (3) a cohort of 17 PV patients with elevated diagnostic Hb/Hct levels but low RCM; and (4) nine PV patients with increased RCM, opposing low Hb/Hct values. All patients were treated according to current PV guidelines (phlebotomies 87%, hydroxyurea 79%, and acetylsalicylic acid 87%). Applying the 2016 WHO criteria significantly increased concordance between RCM and Hb values compared with the 2008 WHO criteria (90 vs. 43% in males and 83 vs. 64% in females). Further analysis of the WHO 2016 PV cohort revealed that increased RCM is associated with increased Hb/Hct (93.8/94.6%). Our study supports and extends the diagnostic impact of the 2016 revised WHO classification for PV by highlighting the importance of characteristic BM findings and implies that Hb/Hct threshold values may be used as surrogate markers for RCM measurements. © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
